- Home
- Companies
- Virpax Pharmaceuticals
- News
- FDA U.S. Food & Drug Administration – ...
FDA U.S. Food & Drug Administration – Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis
Source: Virpax Pharmaceuticals
A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act.
-
Most popular related searches
Customer comments
No comments were found for FDA U.S. Food & Drug Administration – Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis. Be the first to comment!